Next-IO™ Anti-GPC3 × CD3 Therapeutic Bispecific Antibody Program

About This Program

This program aims to develop anti-GPC3 × CD3 therapeutic Bispecific Antibody for immuno-oncology.

For people with cancers, with the progress of their cancer stages, the already-jeopardized self immune response may not sufficient to counter the progression of tumor cells, hence, calling novel molecules to redirect T cells to target on tumor cells. And this can be achieved by a bispecific antibody, BiTE. By recognizing two different epitopes on T cells and cancer cells, Bispecific Antibody is attracting attention as an innovative strategy for cancer immunotherapy. Here we propose a novel strategy of GPC3 bispecific T-cell engager with CD3 (BiTE)for the next HCC treatment.

GPC3

GPC3 belongs to heparin sulfate proteoglycan family, can be immobilized on the cell surface by glycosylphosphatidylinositol anchors. GPC3 can be expressed in a variety of tissues during embryonic development. Beyond that life state, it is a highly tumor-specific antigen in which expression is severely inhibited in most adult tissues.

Highlighted Functions:

Elevated GPC3 expression is reported in a variety of tumor types, such as liver, lung, stomach, ovarian, esophageal, and other forms of cancers, indicating GPC3 is an ideal target to be studies in patients with solid tumors.
In particular, GPC3 is currently used as a diagnostic biomarker to distinguish between HCC and normal liver tissue, benign liver tumors, and other types of metastatic cancer.
There is sufficient evidence to suggest that GPC3 is involved in the malignant transformation of HCC.

Fig.1 Cancer immunotherapy targeting GPC3. (Front. Oncol, 2019)

GPC3 × CD3 in Cancer Studies

Here are some published data about GPC3 × CD3 working as a potential target for cancer immunotherapy.

GPC3 Bispecific Antibody (ERY974) has robust antitumor efficacy against various cancer types.

Anti-GPC3 × CD3 Therapeutic Bispecific Antibody Program

Ongoing Clinical Trials

Currently, only one anti-GPC3 × CD3 therapeutic Bispecific Antibody (called ERY974) is being evaluated in clinical phase 1 trial. Cumulative preclinical data is emerging to supports its important role in cancer progression; however, safety, efficacy, and combination strategies require further confirmation.
There is enough evidence to support GPC3 × CD3 Bispecific Antibody being a compelling target for cancer immunotherapy. In an effort to optimally leverage GPC3-mediated immune response, our next generation of GPC3 targeting treatment attempts to explore combination therapy trials by involving other immunomodulatory agents.

Program Planning and Management

Creative Biolabs has extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.

Anti-GPC3 × CD3 Therapeutic Bispecific Antibody Program

Cooperation

Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop anti-GPC3 × CD3 therapeutic Bispecific Antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.

Here are two ways for your choice, and please contact us for more details.

1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.

With our quality control protocol and knowledge of global regulatory requirements, we can help our partners advance their programs with more chance to succeed. Look forward to cooperating with you in the near future.

Reference

Ishiguron T., et al. Anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors[J]. Science Translational Medicine, 2017, 9(410): eaal4291.

For Research Use Only | Not For Clinical Use